Literature DB >> 27193005

[Rational antibiotic treatment of mediastinitis].

A Ambrosch1.   

Abstract

Mediastinitis occurs as a severe complication of thoracic and cardiac surgical interventions and is the result of traumatic esophageal perforation, conducted infections or as a result of lymphogenic and hematogenic spread of specific infective pathogens. Treatment must as a rule be accompanied by antibiotics, whereby knowledge of the spectrum of pathogens depending on the pathogenesis is indispensable for successful antibiotic therapy. Polymicrobial infections with a high proportion of anaerobes are found in conducted infections of the mediastinum and after esophageal perforation. After cardiac surgery Staphylococci are the dominant pathogens and a nasal colonization with Staphylococcus aureus seems to be a predisposing risk factor. Fungi are the predominant pathogens in immunocompromised patients with consumptive underlying illnesses and can cause acute or chronic forms with granulomatous inflammation. Resistant pathogens are increasingly being found in high-risk patient cohorts, which must be considered for a calculated therapy. For calculated antibiotic therapy the administration of broad spectrum antibiotics, mostly beta-lactams alone or combined with metronidazole is the therapy of choice for both Gram-positive and Gram-negative bacteria inclusive of anaerobes. For patients at risk, additional antibiotic classes with a spectrum against methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) can be administered. Increasing rates of multidrug-resistant Gram-negative bacteria (e.g. Enterobacteriaceae) and non-fermenting bacteria (e.g. Pseudomonas and Acinetobacter) in individual cases necessitates the use of polymyxins (e.g. colistin), new tetracyclines (e.g. glycylglycines) and newly developed combinations of beta-lactams and beta-lactam inhibitors. For treatment of fungal infections (e.g. Candida, Aspergillus and Histoplasma) established and novel azoles, amphotericin B and echinocandins seem to be successful; however, detection of Candida, particularly in mixed infections does not always necessitate treatment. Mediastinitis is still a severe infectious disease with a high mortality, which necessitates an early and broad spectrum antibiotic therapy; however, with respect to optimal duration of therapy and selection of antibiotics, data from good quality comparative studies are lacking.

Entities:  

Keywords:  Bacteria; Fungi; Infection; Methicillin; Vancomycin

Mesh:

Substances:

Year:  2016        PMID: 27193005     DOI: 10.1007/s00104-016-0192-3

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  43 in total

1.  Fibrosing mediastinitis as an untypical complication of tuberculosis: case report.

Authors:  Justyna Fijołek; Elzbieta Wiatr; Katarzyna Błasińska-Przerwa; Kazimierz Roszkowski-Sliz
Journal:  Pol Arch Med Wewn       Date:  2009-11

2.  Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.

Authors:  Yoav Barnea; Anat Lerner; Asaf Aizic; Shiri Navon-Venezia; Eleanor Rachi; Michael W Dunne; Sailaja Puttagunta; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2015-10-30       Impact factor: 5.790

3.  Mucor mediastinitis.

Authors:  B A Connor; R J Anderson; J W Smith
Journal:  Chest       Date:  1979-04       Impact factor: 9.410

4.  The effect of Clostridium difficile infection on cardiac surgery outcomes.

Authors:  Anthony Lemaire; Viktor Dombrovskiy; George Batsides; Peter Scholz; Al Solina; Nicholas Brownstone; Alan Spotnitz; Leonard Y Lee
Journal:  Surg Infect (Larchmt)       Date:  2014-11-17       Impact factor: 2.150

5.  Controlling the usage of intranasal mupirocin does impact the rate of Staphylococcus aureus deep sternal wound infections in cardiac surgery patients.

Authors:  Mary R Nicholson; Laura A Huesman
Journal:  Am J Infect Control       Date:  2006-02       Impact factor: 2.918

6.  In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.

Authors:  A B Macone; B K Caruso; R G Leahy; J Donatelli; S Weir; M P Draper; S K Tanaka; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

7.  Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus.

Authors:  E S Dodds Ashley; D N Carroll; J J Engemann; A D Harris; V G Fowler; D J Sexton; K S Kaye
Journal:  Clin Infect Dis       Date:  2004-05-12       Impact factor: 9.079

Review 8.  New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Curr Opin Crit Care       Date:  2015-10       Impact factor: 3.687

9.  Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.

Authors:  Y Barnea; S Navon-Venezia; B Kuzmenko; N Artzi; Y Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-14       Impact factor: 3.267

10.  Postoperative mediastinitis in cardiac surgery - microbiology and pathogenesis.

Authors:  B Gårdlund; C Y Bitkover; J Vaage
Journal:  Eur J Cardiothorac Surg       Date:  2002-05       Impact factor: 4.191

View more
  1 in total

Review 1.  Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (SEICAV), the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) and the Biomedical Research Centre Network for Respiratory Diseases (CIBERES).

Authors:  Emilio Bouza; Arístides de Alarcón; María Carmen Fariñas; Juan Gálvez; Miguel Ángel Goenaga; Francisco Gutiérrez-Díez; Javier Hortal; José Lasso; Carlos A Mestres; José M Miró; Enrique Navas; Mercedes Nieto; Antonio Parra; Enrique Pérez de la Sota; Hugo Rodríguez-Abella; Marta Rodríguez-Créixems; Jorge Rodríguez-Roda; Gemma Sánchez Espín; Dolores Sousa; Carlos Velasco García de Sierra; Patricia Muñoz; Martha Kestler
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.